Blocking ITK Activity Slows Growth of Malignant Melanoma in Mouse Model
By LabMedica International staff writers Posted on 13 May 2015 |
Image: Molecular model of IL2 inducible T-cell kinase (ITK) enzyme (Photo courtesy of Wikimedia Commons).
Development of malignant melanoma was found to depend to some extent on the activity of the enzyme produced by the gene interleukin-2 (IL2) inducible T-cell kinase (ITK).
Investigators at the University of North Carolina (Chapel Hill, USA) used an ITK-specific monoclonal antibody to probe sections from formalin-fixed paraffin-embedded tumor blocks or melanoma cell line arrays. ITK was visualized by immunohistochemistry (IHC).
Results published in the May 1, 2015, issue of the journal Clinical Cancer Research revealed that ITK was expressed at greater levels in primary and metastatic melanomas than in non-cancerous moles. In metastatic melanoma samples, 91% had higher expression levels than of the non-cancerous moles.
Treatment of melanoma-bearing mice with a low molecular weight ITK inhibitor reduced growth of ITK-expressing xenografts or established native melanomas.
“We have discovered that ITK is highly expressed in melanoma even though it was thought to be restricted to immune cells, and when you inhibit it, you decrease melanoma growth,” said senior author Dr. Nancy E. Thomas, professor of dermatology at the University of North Carolina. “Therefore, we think it is a good potential drug target.”
Related Links:
University of North Carolina
Investigators at the University of North Carolina (Chapel Hill, USA) used an ITK-specific monoclonal antibody to probe sections from formalin-fixed paraffin-embedded tumor blocks or melanoma cell line arrays. ITK was visualized by immunohistochemistry (IHC).
Results published in the May 1, 2015, issue of the journal Clinical Cancer Research revealed that ITK was expressed at greater levels in primary and metastatic melanomas than in non-cancerous moles. In metastatic melanoma samples, 91% had higher expression levels than of the non-cancerous moles.
Treatment of melanoma-bearing mice with a low molecular weight ITK inhibitor reduced growth of ITK-expressing xenografts or established native melanomas.
“We have discovered that ITK is highly expressed in melanoma even though it was thought to be restricted to immune cells, and when you inhibit it, you decrease melanoma growth,” said senior author Dr. Nancy E. Thomas, professor of dermatology at the University of North Carolina. “Therefore, we think it is a good potential drug target.”
Related Links:
University of North Carolina
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples